Chemomab Therapeutics Ltd. American Depositary Share
Organization details
- Legal name
- Chemomab Therapeutics Ltd. American Depositary Share
- Former names
- Anchiano Therapeutics Ltd. BioCancell Ltd.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Israel
- Headquarters city
- TEL Aviv
- Headquarters country
- Israel
- Fiscal year end
- December
- Ticker symbol
- CMMB
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001534248
- EIN
- 81-3676773
Board of directors
-
Alan Charles Moses · DirectorSince 2026
-
Claude Nicaise · DirectorSince 2026
-
George Adi Mor · Director · Chief Executive OfficerSince 2026
-
Gwen A. Melincoff · DirectorSince 2026
-
Jill M. Quigley · DirectorSince 2026
-
Neil Harris Cohen · DirectorSince 2026
-
Nissim Darvish · DirectorSince 2026
Chief executives
Board connections
4 of this board's directors also sit on 6 other boards. 5 are in the same sector.
-
Filana Therapeutics Inc. Same sectorvia Claude Nicaise and Jill M. Quigley
-
Gain Therapeutics Inc. Same sectorvia Claude Nicaise and Gwen A. Melincoff
-
Collegium Pharmaceutical Inc. Same sectorvia Gwen A. Melincoff
-
Protalix BioTherapeutics Inc. (DE) Same sectorvia Gwen A. Melincoff
-
Sarepta Therapeutics Inc. Same sectorvia Claude Nicaise
- via Alan Charles Moses
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $20,246
- 2 purchases by 1 insider
- Sold, last 12 months
- $6,516
- 2 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 28, 2026 | Neil Harris Cohen Director | Open-market sale | −1,000 | $2.80 | $2,800 |
| Aug 27, 2026 | Neil Harris Cohen Director | Open-market sale | −1,304 | $2.85 | $3,716 |
| May 29, 2026 | George Adi Mor Director, Officer (Chief Executive Officer) | Open-market purchase | −4,878 | $2.05 | $10,000 |
| May 29, 2026 | George Adi Mor Director, Officer (Chief Executive Officer) | Open-market purchase | −4,926 | $2.08 | $10,246 |
| May 29, 2026 | George Adi Mor Director, Officer (Chief Executive Officer) | Other | −31,712 | — | — |
| May 29, 2026 | George Adi Mor Director, Officer (Chief Executive Officer) | Other | −18,750 | — | — |
| Jan 3, 2023 | OrbiMed Israel BioFund GP Limited Partnership 10% owner | Open-market sale | −266,376 | $3.34 | $889,696 |
| Jan 3, 2023 | George Adi Mor Director, Officer (Chief Scientific Officer) | Open-market sale | −7,700 | $5.03 | $38,731 |
| Jan 3, 2023 | OrbiMed Israel BioFund GP Limited Partnership 10% owner | Open-market sale | −70,524 | $4.51 | $318,063 |
| Jan 3, 2023 | George Adi Mor Director, Officer (Chief Scientific Officer) | Open-market sale | −6,100 | $5.03 | $30,683 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Chemomab Therapeutics Ltd. American Depositary Share
Who is the CEO of Chemomab Therapeutics Ltd. American Depositary Share?
George Adi Mor has been Chemomab Therapeutics Ltd. American Depositary Share's Chief Executive Officer since March 2026.
How many directors are on Chemomab Therapeutics Ltd. American Depositary Share's board?
Chemomab Therapeutics Ltd. American Depositary Share's board has 7 directors: Alan Charles Moses, Claude Nicaise, George Adi Mor, Gwen A. Melincoff, Jill M. Quigley, Neil Harris Cohen and Nissim Darvish.
Are Chemomab Therapeutics Ltd. American Depositary Share insiders buying or selling shares?
Over the last 12 months, Chemomab Therapeutics Ltd. American Depositary Share insiders bought $20,246 of shares in 2 purchases and sold $6,516 of shares in 2 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="chemomab-therapeutics-ltd-american-depositary-share"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.